Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Safety of Henagliflozin Combined with Continuous Subcutaneous Insulin Infusion in the Treatment of Type 2 Diabetes Mellitus Based on Continuous Glucose Monitoring System

NCT05677334 is registered in ClinicalTrials.gov with First Affiliated Hospital of Guangxi Medical University as lead sponsor.

NCT NCT05677334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Safety of Henagliflozin Combined with Continuous Subcutaneous Insulin Infusion in the Treatment of Type 2 Diabetes Mellitus Based on Continuous Glucose Monitoring System
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2023
Completion date
October 30, 2024
Enrollment
210 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2diabetes